| 31 | 0 | 67 |
| 下载次数 | 被引频次 | 阅读次数 |
目的 建立酒精相关性肝病（ALD）患者药物治疗管理（MTM）路径，为ALD患者的MTM提供依据。方法 基于临床证据、临床指南与相关文献，系统性梳理ALD患者的药物使用原则、常见不良反应、用药注意事项及后期随访要点。结果 建立了ALD患者MTM路径，该路径涵盖了从用药评估、风险识别和长期随访的全过程。结论 建立的MTM路径可以为临床ALD患者的MTM提供循证医学和药学依据，以促进临床合理用药，提高患者用药依从性，保障患者用药安全。
Abstract：AIM To establish a pharmacist-led medication therapy management(MTM) pathway for patients with alcohol-associated liver disease(ALD), providing a reference for MTM in ALD patients. METHODS Based on the clinical evidence, clinical guidelines and related literature, we systematically reviewed and synthesized the key principles of pharmacotherapy, common adverse drug reactions, essential monitoring parameters, and critical elements of long-term follow-up for patients with ALD. RESULTS A structured clinical guidance pathway was developed from the pharmacist's perspective, which encompassed the entire continuum of care, from initial medication reconciliation and risk assessment to ongoing long-term follow-up. CONCLUSION The established MTM pathway for ALD patients can provide evidence-based medicine and pharmaceutical basis for MTM in clinical to promote rational drug use, improve patient medication compliance and ensure patient medication safety.
[1]MACKWIAK B, FU Y J, MACCIONI L, et al. Alcohol-associated liver disease[J]. J Clin Invest, 2024, 134(3):e176345.
[2]中华医学会,中华医学会杂志社,中华医学会消化病学分会,等.酒精性肝病基层诊疗指南(2019年)[J].中华全科医师杂志,2020, 19(11):990.
[3]GRISSA D, NYTOFT RASMUSSEN D, KRAG A, et al. Alcoholic liver disease:a registry view on comorbidities and disease prediction[J]. PLoS Comput Biol, 2020, 16(9):e1008244.
[4]国家卫生健康委,国家中医药局.全面提升医疗质量行动计划(2023—2025年)[EB/OL].(2023-05-26)[2024-09-20].https://www.gov.cn/zhengee/zhengceku/202305/content_6883704.htm.
[5]国家卫生健康委办公厅.患者安全专项行动方案(2023—2025年)[EB/OL].(2023-09-27)[2024-09-27]. https://www.gow.en/zhengce/zhengceku/202310/content_6908044.htm.
[6]付晓纯,任春霞,张思棋,等.慢性肾脏病患者药物治疗管理和临床药学实践的系统评价[J].中国临床药学杂志, 2024, 33(7):487.
[7]WANG X, WANG S H, YU X J, et al. Impact of pharmacist-led medication therapy management in ambulatory elderly patients with chronic diseases[J]. Br J Clin Pharmacol, 2021, 87(7):2937.
[8]SHAH N D, VENTURA-COTS M, ABRALDES J G, et al. Alcoholrelated liver disease is rarely detected at early stages compared with liver diseases of other etiologies worldwide[J]. Clin Gastroenterol Hepatol, 2019, 17(11):2320.
[9]JOPHLIN L L, SINGAL A K, BATALLER R, et al. ACG clinical guideline:alcohol-associated liver disease[J]. Am J Gastroenterol, 2024, 119(1):30.
[10]ADDOLORATO G, ABENAVOLI L, DALLIO M, et al. Alcohol associated liver disease 2020:a clinical practice guideline by the Italian Association for the Study of the Liver(AISF)[J]. Dig Liver Dis, 2020, 52(4):374.
[11]LOUVET A, TRABUT J B, MORENO C, et al. Management of alcohol-related liver disease:the French Association for the Study of the Liver and the French Alcohol Society clinical guidelines[J].Liver Int, 2022, 42(6):1330.
[12]World Health Organization. International statistical classification of diseases and related health problems 10th revision(ICD10)version:2019[EB/OL].(2019-10-19)[2024-10-22]. https://icd.who.int/browse10/2019/en.
[13]PRINCE D S, NASH E, LIU K. Alcohol-associated liver disease:evolving concepts and treatments[J]. Drugs, 2023, 83(16):1459.
[14]JOHNSON A L, HAYWARD K L. Managing medicines in alcoholassociated liver disease:a practical review[J]. Aust Prescr,2021, 44(3):96.
[15]BERTHA M, CHOI G, MELLINGER J. Diagnosis and treatment of alcohol-associated liver disease:a patient-friendly summary of the2019 AASLD guidelines[J]. Clin Liver Dis, 2021, 17(6):418.
[16]CHAUDHRY H, SOHAL A, IQBAL H, et al. Alcohol-related hepatitis:a review article[J]. World J Gastroenterol, 2023,29(17):2551.
[17]TADOKORO T, MORISHITA A, HIMOTO T, et al. Nutritional support for alcoholic liver disease[J]. Nutrients, 2023, 15(6):1360.
[18]ALUKAL J J, NAQVI H A, THULUVATH P J. Vaccination in chronic liver disease:an update[J]. J Clin Exp Hepatol, 2022,12(3):937.
基本信息:
DOI：10.19577/j.1007-4406.2026.01.002
中图分类号:R575;R969
引用信息:
[1]姜康,张宁,吕迁洲,等.酒精相关性肝病患者药物治疗管理路径的建立[J].中国临床药学杂志,2026,35(01):7-12.DOI:10.19577/j.1007-4406.2026.01.002.
基金信息:
上海市卫健委卫生行业临床研究专项（编号202340281）